Related Experiment Videos
Overlap syndromes and mixed connective tissue disease
1Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, Bath, UK.
Current Opinion in Rheumatology
|December 1, 1991
Summary
Connective tissue disease overlap syndromes are identified by specific autoantibody markers. These markers, such as anti-U1-ribonucleoprotein, help classify patients and may reveal disease origins.
Area of Science:
- Rheumatology
- Immunology
- Internal Medicine
Background:
- Connective tissue diseases (CTDs) lack known etiology, necessitating classification via clinical and laboratory features.
- Overlap syndromes, presenting with features of multiple CTDs, affect up to 25% of patients.
- Identifying autoantibody markers is crucial for subclassifying heterogeneous overlap syndromes.
Purpose of the Study:
- To explore the role of autoantibody markers in classifying CTD overlap syndromes.
- To investigate the association between specific antibodies and distinct clinical presentations.
- To provide insights into the pathogenesis and etiology of CTDs.
Main Methods:
- Review of clinical and laboratory features in CTD patients.
- Analysis of autoantibody profiles, including anti-U1-ribonucleoprotein, anti-Ku, anti-U2-ribonucleoprotein, and anti-Jo-1.
- Correlation of antibody presence with specific CTD manifestations and overlap patterns.
Main Results:
- Anti-U1-ribonucleoprotein antibodies are linked to overlap syndromes featuring systemic lupus erythematosus with systemic sclerosis or myositis.
- Antibodies to polymyositis-scleroderma (PM/Scl), Ku, and U2-ribonucleoprotein are associated with systemic sclerosis and polymyositis overlaps.
- Anti-Jo-1 antibodies are specifically associated with polymyositis and pulmonary fibrosis.
Conclusions:
- Autoantibody profiling aids in subclassifying CTD overlap syndromes.
- Specific antibody-phenotype associations offer prognostic and therapeutic guidance.
- Further research into antibody origins and targets may illuminate CTD pathogenesis and etiology.